Drug Profile
PF 4605412
Alternative Names: PF-04605412; PF-4605412Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antibodies; Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Integrin alpha 5 beta 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Feb 2013 Discontinued - Phase-I for Solid tumours in United Kingdom (IV)
- 26 Feb 2013 Discontinued - Phase-I for Solid tumours in USA (IV)
- 26 Feb 2013 Pfizer terminates phase I trial in Solid tumours in the USA and the UK (NCT00915278)